The only thing "stricter" is the non memantine part of the trial. Luckily they only have to be off the drug a short period of time, but may be why we have or haven't started dosing yet. Not having to get an additional 50 patients up and treated is much more of a time saver than most would imagine. We'll know the data from our trial before many of these other trials even get kicked off good.
Great week here. Would love to see this trade in the 12 to 15 range for awhile.
News 
Market Data 
Discover 
